Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences and Kite ally with Sangamo Therapeutics on cancer research

Gilead Sciences and Kite ally with Sangamo Therapeutics on cancer research

23rd February 2018

Gilead Sciences and Kite have announced a new drug research collaboration with Sangamo Therapeutics in the field of oncology.

The worldwide collaboration will leverage Sangamo's zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology, with the aim of creating new drugs for autologous and allogeneic use in treating different cancers.

Allogeneic cell therapies from healthy donor cells or renewable stem cells provide a potential new treatment option that can be accessed directly within the oncology infusion centre, thereby reducing the time patients need to wait for an infusion.

The alliance could see Sangamo receive up to $3.01 billion (GBP 2.15 billion) in milestone-based payments, aggregated across ten or more products utilising Sangamo's technology, in addition to an upfront payment of $150 million.

Kite will be responsible for all development, manufacturing and commercialisation activities, as well as agreed-upon expenses incurred by Sangamo.

Dr John Milligan, Gilead's president and chief executive officer, said: "We look forward to working with Sangamo to accelerate our efforts to develop next-generation autologous cell therapies, as well as allogeneic treatments that can be accessed more conveniently in the hospital setting for people living with cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.